Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...